Home ProductsAnti Estrogen Steroids

99% Pure Anti Estrogen Steroids CAS 82640-04-8 Raloxifene Hydrochloride

99% Pure Anti Estrogen Steroids CAS 82640-04-8 Raloxifene Hydrochloride

  • 99% Pure Anti Estrogen Steroids CAS 82640-04-8 Raloxifene Hydrochloride
99% Pure Anti Estrogen Steroids CAS 82640-04-8 Raloxifene Hydrochloride
Product Details:
Place of Origin: China
Brand Name: www.steroidaily.com
Certification: ISO9001
Model Number: 82640-04-8
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Price: 1USD/g
Packaging Details: Special disguised packaging or as your demand
Delivery Time: within 24hours after confirm your payment
Payment Terms: T/T, ,
Supply Ability: plent of stock
Contact Now
Detailed Product Description
CAS: 82640-04-8 Assay: 99%
Molecular Formula: C28H28ClNO4S Molecular Weight: 510.04
Appearance: Light Yellow Powder Grade: Pharmaceutical Grade
Storage: Shading, Confined Preservation Express: UPS,TNT,DHL,EMS,HKEMS,FEDEX
Delivery Time: Within 24h After Confirm Your Payment Email: Service01@chembj.com
High Light:

anti estrogen supplements


natural anti estrogen

99% Pure Anti Estrogen Steroids CAS 82640-04-8 Raloxifene Hydrochloride



Raloxifene hydrochloride

Alias: Raloxifene HCl; KEOXIFENE; AKOS 92138
CAS: 82640-04-8
Purity: 99%
MF: C28H28ClNO4S
MW: 510.04
Appearance: Light yellow powder
Related Substances: Pharmaceutical Grade
Storage: Shading, confined preservation
Usage: It is used in the prevention of osteoporosis in postmenopausal women.




Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).


May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

Side effect: Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i. e., can cause developmental abnormalities such as birth defects.



Actions mediated largely through binding to estrogen receptors, which results in activation of certain estrogenic pathways and blockade of others. Appears to act as an estrogen agonist in bone. Decreases bone resorption and turnover, increases bone mineral density.

Special Populations:

Renal Function Impairment
Raloxifene concentrations are elevated in renal impairment. Use with caution.

Hepatic Function Impairment:

Raloxifene Cl is reduced in patients with hepatic impairment; the pharmacokinetics were not studied in patients with moderate or severe hepatic impairment. Use with caution.

Indications and Usage:

Raloxifene is contraindicated in lactating women or women who are or may become pregnant, in women with active or past history of venous thromboembolic events, including deep vein thrombosis,pulmonary embolism, and retinal vein thrombosis and in women known to be hypersensitive to raloxifene.
For the prevention and treatment of osteoporosis in postmenopausal women; reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis; reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.


Unlabeled Uses:

Treatment of uterine leiomyomas; treatment of pubertal gynecomastia; prevention of bone loss in men with prostate cancer.
Women who are or may become pregnant; breast-feeding mothers; women with active or history of venous thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism, and retinal vein thrombosis; allergy to raloxifene or other constituents of the product.

General Advice:

May be taken any time of day without regard to meals.
For reduction in risk of invasive breast cancer, the optimum duration of treatment is not known.
For osteoporosis treatment or prevention, add supplemental calcium and/or vitamin D to the diet if daily intake is inadequate.
Store at 59° to 86°F.


Adjust the start time of the gradient step based on the instrument's dwell volume.] Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: the resolution, R, between the raloxifene and raloxifene N-oxide peaks is not less than 3.0; and the tailing factor for the raloxifene peak is not more than 2.0.
Separately inject equal volumes (about 10 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms for not less than two times the retention time of the raloxifene peak, and measure all of the peak responses. Calculate the percentage of each impurity in the portion of Raloxifene Hydrochloride taken by the formula



Appearance White &off-white powder Conform

Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water
Identifications Infrared Absorption Conform
  Chloride Conform
Tests Loss on drying ≤0.5% 0.4%
  Residue on ignition ≤0.1% 0.06%
  Heavy metals ≤10ppm Conform

RRelated substances
  ≤0.20 % 0.10%
  Any unspecified individual impurity 2 ≤0.10% Max. 0.08%
  Total impurities ≤0.50% 0.40%
Assay Raloxifene HCl ≥98.0% 99.0%


Packaging & Delivery:

1. Sufficient stock.
2. Sophisticated and professional logistic agent.
3. Well-trained and disciplined packing team.
4. Packing pictures and tacking code are provided within 12 hours after receiving the payment.
5. After-sale service.


Our Advantages:

1.Good quality with free samples .
1)Good quality is the basic of our goal.
2)We can afford free samples to be tested.

2.Good feedback.
1)We are a high-tech company in China for many years.
2)98% of our products have exported to UK, USA, Germany, Spain, Australia, Middle East and many other countries. and we have got very good feedback from our customers.

3.Safe and fast delivery.
1)We have stock, so parcel can be sent out in 24 hours after payment. Tracking number is available.
2)We have special way could ship 0.01kg to 3.5kg products a time. And ship the liquid in special bottles.
3)Customs pass rate ≥ 99%

4.Good after-sales service.
Tell the package update ASAP, and will try best solve when customer encountered various problems.


99% Pure Anti Estrogen Steroids CAS 82640-04-8 Raloxifene Hydrochloride 0

Contact Details

Contact Person: Alex

Tel: 86-18171373082

Send your inquiry directly to us (0 / 3000)

Other Products